RxDoctor Payments Data

Michael Rie, MD

Family Medicine · Austin, TXNPI 1902009301

Payments from drug & device makers

$10,549in general payments, 2019–2025

Across 724 payments — averaging $14.57 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • GSK$2K
  • Novo Nordisk$1K
  • AbbVie$864
  • Lilly USA, LLC$825
  • AstraZeneca$637
  • Boehringer Ingelheim$625
  • plus $5K from 39 others

What the payments were for

  • Food & beverage$10,535100%
  • Education$140%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$10,549 in reported general payments places this provider in the 90th percentile of 8,760 family medicine providers in Texas.

See all family medicine providers in Texas

Medicare billing

Part B allowed, 2024
$49,551
Medicare patients
156
Services billed
660

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OzempicSemaglutide22$33,110
TrulicityDulaglutide17$31,781
MounjaroTirzepatide23$30,987
Synjardy XrEmpagliflozin/Metformin Hcl18$25,516
Xigduo XrDapaglifloz Propaned/Metformin14$9,787
Trijardy XrEmpaglifloz/Linaglip/Metformin12$6,897
Estradiol12$2,370
Atorvastatin Calcium205$2,070
SynthroidLevothyroxine Sodium37$1,910
Liothyronine Sodium32$1,509
Levothyroxine Sodium88$1,304
Rosuvastatin Calcium75$1,044
Tamsulosin Hcl42$888
Lisinopril54$712
Valsartan-HydrochlorothiazideValsartan/Hydrochlorothiazide13$621

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Lilly USA, LLCTrulicity, Mounjaro$825$62,76940 claims
Novo NordiskOzempic$1,001$33,11022 claims
Boehringer IngelheimSynjardy Xr, Trijardy Xr$625$32,41330 claims
AbbVieSynthroid$864$1,91037 claims
Amneal Pharmaceuticals LLCLevothyroxine Sodium$59$1,30488 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 8,760 family medicine providers in Texas.

Other family medicine in Austin

See the full list for Texas

Where these figures come from

Is this you, or does something look wrong? →